Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
2
50%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
N/ANon-phased studies
2(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(2)
Other(2)

Detailed Status

Completed2
unknown2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
N/A

Trials by Phase

N/A2 (100.0%)

Trials by Status

completed250%
unknown250%

Recent Activity

0 active trials
Showing 4 of 4
completednot_applicable

C5a Receptor Expression - COVID-19 (C5-COV)

NCT04369820
unknown

Establish the Referenc Range of Antiphospholipid Antibody in Healthy Preganany Women

NCT05883189
unknownnot_applicable

Study of Constitutional Platelet Disease

NCT04419987
completed

Investigation of the Serum Mucoprotein 3 (MUC3) Protein Levels in Gestational Hypertensive Disease

NCT04421183

Clinical Trials (4)

Showing 4 of 4 trials
NCT04369820Not Applicable

C5a Receptor Expression - COVID-19 (C5-COV)

Completed
NCT05883189

Establish the Referenc Range of Antiphospholipid Antibody in Healthy Preganany Women

Unknown
NCT04419987Not Applicable

Study of Constitutional Platelet Disease

Unknown
NCT04421183

Investigation of the Serum Mucoprotein 3 (MUC3) Protein Levels in Gestational Hypertensive Disease

Completed

All 4 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
4